Related Experiment Video

Updated: Mar 14, 2026

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking
14:21

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking

Published on: August 6, 2013

18.9K

Pharmacogenetic Optimization of Smoking Cessation Treatment

Meghan J Chenoweth1, Rachel F Tyndale2

  • 1Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ONT, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ONT, Canada.

Trends in Pharmacological Sciences
|October 8, 2016
PubMed

Insights

Genetic factors influence smoking cessation success. Understanding genetic variations can personalize treatments, improving quit rates and reducing harm for smokers. This approach aims to enhance current therapies.

Area of Science:

  • Pharmacogenetics
  • Genetics
  • Nicotine Metabolism

Background:

  • Smoking cessation rates remain low with current treatments.
  • Genetic factors significantly impact smoking cessation outcomes.
  • Variation in nicotine metabolism and medication targets affects success.

Purpose of the Study:

  • To review advances in understanding genetic variation's role in smoking cessation.
  • To explore tailoring therapies based on genetic profiles.
  • To increase quit rates and reduce tobacco-related harm.

Main Methods:

  • Review of scientific literature on genetic variation and smoking cessation.
  • Analysis of genetic factors influencing nicotine and medication metabolism.
  • Examination of genetic targets for nicotine and cessation medications.

Main Results:

  • Smokers with slow nicotine metabolism show better success with behavioral counseling and nicotine patches.
  • Genetic variations in drug-metabolizing enzymes and receptor targets are key.
  • Personalized approaches show promise for improving cessation outcomes.

Conclusions:

  • Genetic insights can optimize smoking cessation strategies.
  • Tailoring therapy based on genetic profiles can increase quit rates.
  • Personalized pharmacogenetics holds potential for reducing tobacco-related harm.
Keywords:
metabolismnicotinepharmacogeneticssmoking cessationtobaccotreatment

More Related Videos

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder07:51

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder

Published on: June 18, 2018

11.2K
Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke09:50

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke

Published on: February 12, 2015

11.7K

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
87
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
61
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
83
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
110
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
90